The immunological profile of tumor-bearing animals determines the outcome ofcancer immunotherapy.

摘要

Do cancer patients responding to immunotherapy have immunological profiles thatinfluence the therapeutic outcome, or do they develop efficient antitumorresponses only upon immunotherapy? We came across this "chicken or the egg"dilemma when treating secondary liver tumors with Semliki Forest virusesexpressing interleukin-12. In our system, the "egg," that is, the pre-treatmentimmunological profile, seemed to make the difference. The properties of aneffective antitumor response were also defined.